Overview
Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes mellitus in adults, adolescents, and children aged >1 year. This publication reviews its efficacy and safety, and the limitations of the evidence.